ALIGOS THERAPEUTICS INC

Aligos Therapeutics Inc. is a clinical-stage biopharmaceutical company whose core business model involves the discovery and development of novel therapeutics. The development pathway for these drug candidates, as is standard in the industry, requires extensive preclinical testing in animal models to assess safety, efficacy, and pharmacokinetics before human trials can commence. The company's public research, including presentations on candidates like ALG-097558 for coronaviruses, explicitly details studies conducted in animal species. This reliance on animal testing is a fundamental and non-negotiable component of its research and development operations.

The company is flagged by third-party screening resources, including Cruelty Free Investors, which identifies companies whose business activities exploit animals. For a preclinical biotech firm like Aligos, animal testing is not a peripheral activity but the central mechanism for advancing its pipeline. The scale of this exploitation is inherent to its business; each drug candidate requires iterative testing across multiple animal models, with the number of animals used scaling with the number of programs in development. Aligos has no marketed products and derives 100% of its value from its preclinical and clinical pipeline, which is built upon this foundational use of animals.